Our Platform
Our proprietary mini-Life Platform includes the award-winning mini-Heart Technology which offers a range of bioengineered human heart constructs, including the world’s first human heart-in-a-jar, as healthy and diseased human hearts for testing toxicity and efficacy.
Our Revolutionary Approach
This platform substantially increases the chances of saving and addressing maladies for millions with new discoveries
and far greater affordability for the patients.
Single Cell
Novoheart's human ventricular Cardiomyocytes (hvCMs) are terminally differentiated cardiomyocytes derived from human pluripotent stem cells (hPSCs) using Novoheart’s proprietary differentiation method. These cells have been extensively characterized for their electrophysiology, calcium homeostasis, transcriptome, microRNAome, and proteome.
They exhibit ventricular-like action potentials and express ventricular-specific myosin light chain MLC2v. With virtually homogeneous ventricular properties, these cells provide the consistency necessary to achieve reliable and reproducible results in downstream applications.
hvCM
Biologics Ventricular Specific CM differentiation kit
hESC-vCM
hESC-vCM
hiPSC-vCM
hiPSC-vCM
Media hvCM maintenance medium
Contractility
Contractile performance is an essential function of the human heart, yet conventional 2-D cardiomyocyte cultures are inadequate for assessing contractility as they cannot perform physiological contractions on rigid plasticware. Tissue engineering offers a superior contractile assay in the form of Novoheart’s human ventricular Cardiac Tissue Strip (hvCTS), which is structurally and functionally similar to native trabecular muscle. This assay consists of aligned hvCMs in 3-D hydrogel mixture that is constructed using Medera’s custom-designed bioreactor with integrated force-sensing posts at the ends. This model has been validated as a sensitive and reliable predictor of clinical effects of drugs or pathologies on cardiac contractility.
hvCTS
Biologics CTS Fabrication Kit
µCTS Fabrication Kit
µCTS Fabrication Kit
Media Maintenance medium
Instruments CTScreen System
Software mini-Heart T-Monitor
mini-Heart T-Processor
mini-Heart T-Analyzer
Consumables 1-CTS Cartridge
3-CTS Cartridge
6-µCTS Cartridge
96-well µCTS Plate
EP and Arrhythmias
Effective modeling of arrhythmias in vitro is challenging: by definition, they are multicellular events that can only be recorded by monitoring conduction patterns in electrically coupled cardiomyocytes. Conventional assays can only use surrogate markers for arrhythmia: the hERG assay, standard in the industry, for example, uses inhibition of a single potassium channel exogenously expressed in non-cardiac cell lines as an indicator for proarrhythmic risk. Although these remain the standard tests for arrhythmogenicity, global drug regulators recognize their pitfalls and are actively seeking better alternatives, notably in the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative of the FDA. Human pluripotent stem cell-derived cardiomyocytes are inherently prone to arrhythmic events when cultured as randomly oriented monolayers. Novoheart’s human ventricular Cardiac Anisotropic Sheet (hvCAS) assay utilizes specially designed microgrooved substrates that physically guide hvCMs to align in a similar manner to that in the native human ventricle. The aligned cells show anisotropic electrical conduction which has been validated to reduce the baseline arrhythmogenicity compared to monolayers without a cardiomimetic preferential conduction axis.
hvCAS
Biologics CAS Fabrication Kit
Media Maintenance medium
Instruments CAScreen System
Software mini-Heart A-Analyzer
Consumables µPatterned PS Substrate
4-CAS Module
EP and Pressure
Novoheart’s fluid-ejecting 3-D human ventricular Cardiac Organoid Chamber (hvCOC), a.k.a. “human heart-in-a-jar” is the only technology available to date that enables the clinically informative assessment of human cardiac pump performance which no other human engineered heart tissues on the market are capable of. Combined with complementary custom-designed hardware and software, the best-in-class “human
heart-in-a-jar” allows drug screening and disease modeling with unprecedented biofidelity.
hvCOC
Biologics - COC Fabrication Kit
µCOC Fabrication Kit
Media - Maintenance medium
Instruments - COScreen System
Software - mini-Heart O-Monitor
mini-Heart O-Processor
mini-Heart O-Analyzer
Consumables - 1-COC Mold
24-μCOC Plate
Single Cell
Novoheart's human ventricular Cardiomyocytes (hvCMs) are terminally differentiated cardiomyocytes derived from human pluripotent stem cells (hPSCs) using Novoheart’s proprietary differentiation method. These cells have been extensively characterized for their electrophysiology, calcium homeostasis, transcriptome, microRNAome, and proteome. They exhibit ventricular-like action potentials and express ventricular-specific myosin light chain MLC2v. The hvCMs are the building blocks for the other mini-Heart assays. With virtually homogeneous ventricular properties, these cells provide the consistency necessary to achieve reliable and reproducible results in downstream applications.
Biologics
Ventricular Specific CM differentiation kit
hESC-vCM
hiPSC-vCM
Media
Maintenance Medium
Electrophysiology and Arrhythmias
Effective modeling of arrhythmias in vitro is challenging: by definition, they are multicellular events that can only be recorded by monitoring conduction patterns in electrically coupled cardiomyocytes. Conventional assays can only use surrogate markers for arrhythmia: the hERG assay, standard in the industry, for example, uses inhibition of a single potassium channel exogenously expressed in non-cardiac cell lines as an indicator for proarrhythmic risk. Although these remain the standard tests for arrhythmogenicity, global drug regulators recognize their pitfalls and are actively seeking better alternatives, notably in the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative of the FDA. Human pluripotent stem cell-derived cardiomyocytes are inherently prone to arrhythmic events when cultured as randomly oriented monolayers. Novoheart’s human ventricular Cardiac Anisotropic Sheet (hvCAS) assay utilizes specially designed microgrooved substrates that physically guide hvCMs to align in a similar manner to that in the native human ventricle. The aligned cells show anisotropic electrical conduction which has been validated to reduce the baseline arrhythmogenicity compared to monolayers without a cardiomimetic preferential conduction axis.
Biologics
CAS Fabrication Kit
Media
Maintenance medium
Instruments
CAScreen System
Software
mini-Heart A-Analyzer
Consumables
µPatterned PS Substrate
4-CAS Module
Contractility
Contractile performance is an essential function of the human heart, yet conventional 2-D cardiomyocyte cultures are inadequate for assessing contractility as they cannot perform physiological contractions on rigid plasticware, and cell shortening is not an accurate surrogate for force generation. Tissue engineering offers a superior contractile assay in the form of Novoheart’s human ventricular Cardiac Tissue Strip (hvCTS), which is structurally and functionally similar to native trabecular muscle. This assay consists of aligned hvCMs in 3-D collagen hydrogel mixture that is constructed using Medera’s custom-designed bioreactor with integrated force-sensing posts at the ends. This model has been validated as a sensitive and reliable predictor of clinical effects of drugs or pathologies on cardiac contractility.
Biologics
CTS Fabrication Kit
µCTS Fabrication Kit
µCTS Fabrication Kit
Media
Maintenance medium
Instruments
CTScreen System
Software
mini-Heart T-Monitor
mini-Heart T-Processor
mini-Heart T-Analyzer
Consumables
1-CTS Cartridge
3-CTS Cartridge
6-µCTS Cartridge
96-well µCTS Plate
Electrophysiology and Pump Function
Novoheart’s fluid-ejecting 3-D human ventricular Cardiac Organoid Chamber (hvCOC), a.k.a. “human heart-in-a-jar” is the only commercially available technology to date that enables the clinically informative assessment of human cardiac pump performance, which is not possible with other human engineered heart tissues on the market. Combined with complementary custom-designed hardware and software, the best-in-class “human heart-in-a-jar” allows drug screening and disease modeling with unprecedented biofidelity.
Biologics
COC Fabrication Kit
µCOC Fabrication Kit
Media
Maintenance medium
Instruments
COScreen System
Software
mini-Heart O-Monitor
mini-Heart O-Processor
mini-Heart O-Analyzer
Consumables
1-COC Mold
24-μCOC Plate
